Keros Therapeutics (NASDAQ:KROS) Downgraded by Zacks Research to Hold

Keros Therapeutics (NASDAQ:KROS) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday. Wedbush raised their price objective on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, Oppenheimer reiterated an “outperform” rating and set a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.38.

Keros Therapeutics Trading Down 8.9%

Keros Therapeutics stock opened at $18.54 on Thursday. The firm has a market cap of $564.84 million, a P/E ratio of 12.04, a P/E/G ratio of 0.25 and a beta of 0.89. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $22.55. The firm has a 50-day moving average of $18.54 and a 200-day moving average of $16.05.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.Keros Therapeutics’s quarterly revenue was up 3585.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.41) EPS. Research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its stake in shares of Keros Therapeutics by 163.7% in the first quarter. Invesco Ltd. now owns 33,266 shares of the company’s stock worth $339,000 after buying an additional 20,650 shares in the last quarter. Corebridge Financial Inc. increased its position in shares of Keros Therapeutics by 6.4% during the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock valued at $165,000 after acquiring an additional 972 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Keros Therapeutics by 16,297.6% in the 1st quarter. Cubist Systematic Strategies LLC now owns 198,411 shares of the company’s stock worth $2,022,000 after acquiring an additional 197,201 shares during the last quarter. AQR Capital Management LLC bought a new position in Keros Therapeutics in the 1st quarter valued at approximately $226,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after purchasing an additional 2,982 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.